Radiopharm Theranostics (RAD) KOL Event summary

Introduction and agenda

• Webinar focused on the unmet medical need for patients with suspected recurrent brain metastases from solid tumors and the development of a novel imaging agent, RAD-101.

• Previous webinars covered prostate cancer agents; this session centers on brain metastases and the clinical development of RAD-101.

KOL background and credentials

• Dr. Ramji Rajendran is a radiation oncologist with expertise in advanced therapeutic techniques and research in hormone-dependent tumors.

• He directs the Department of Radiation Oncology and the Illinois Gamma Knife Center, with extensive experience in radiosurgery.

Market insights and analysis

• Brain metastases are five times more common than primary brain tumors, with increasing incidence due to improved cancer survival.

• Lung, breast, colon, kidney, and melanoma are the most common sources of brain metastases.

• In the U.S., about 300,000 new cases of brain metastases are diagnosed annually.

• Current standard imaging (MRI) is insufficient for distinguishing recurrence from treatment effects.